Found: 32
Select item for more details and to access through your institution.
Exploring Novel Frontiers: Leveraging STAT3 Signaling for Advanced Cancer Therapeutics.
- Published in:
- Cancers, 2024, v. 16, n. 3, p. 492, doi. 10.3390/cancers16030492
- By:
- Publication type:
- Article
Targeting Replicative Stress and DNA Repair by Combining PARP and Wee1 Kinase Inhibitors Is Synergistic in Triple Negative Breast Cancers with Cyclin E or BRCA1 Alteration.
- Published in:
- Cancers, 2021, v. 13, n. 7, p. 1656, doi. 10.3390/cancers13071656
- By:
- Publication type:
- Article
Cytoplasmic Cyclin E Is an Independent Marker of Aggressive Tumor Biology and Breast Cancer-Specific Mortality in Women over 70 Years of Age.
- Published in:
- Cancers, 2020, v. 12, n. 3, p. 712, doi. 10.3390/cancers12030712
- By:
- Publication type:
- Article
Cyclin E deregulation alters the biologic properties of ovarian cancer cells.
- Published in:
- Oncogene, 2004, v. 23, n. 15, p. 2648, doi. 10.1038/sj.onc.1207408
- By:
- Publication type:
- Article
How will we recruit, train, and retain physicians and scientists to conduct translational cancer research?
- Published in:
- Cancer (0008543X), 2015, v. 121, n. 6, p. 806, doi. 10.1002/cncr.29033
- By:
- Publication type:
- Article
Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence.
- Published in:
- Breast Cancer Research, 2014, v. 16, n. 6, p. 1, doi. 10.1186/s13058-014-0497-4
- By:
- Publication type:
- Article
Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Elafin, an inhibitor of elastase, is a prognostic indicator in breast cancer.
- Published in:
- Breast Cancer Research, 2013, v. 15, n. 1, p. 1, doi. 10.1186/bcr3374
- By:
- Publication type:
- Article
Elafin, an inhibitor of elastase, is a prognostic indicator in breast cancer.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Author reply.
- Published in:
- Cancer (0008543X), 2005, v. 104, n. 8, p. 1780
- By:
- Publication type:
- Article
Specific, reversible G1 arrest by UCN-01 in vivo provides cytostatic protection of normal cells against cytotoxic chemotherapy in breast cancer.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Targeting low molecular weight cyclin E (LMW-E) in breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2012, v. 132, n. 2, p. 575, doi. 10.1007/s10549-011-1638-4
- By:
- Publication type:
- Article
Cyclin E deregulation is an early event in the development of breast cancer.
- Published in:
- 2009
- By:
- Publication type:
- Report
LMW cyclin E and its novel catalytic partner CDK5 are therapeutic targets and prognostic biomarkers in salivary gland cancers.
- Published in:
- Oncogenesis, 2021, v. 10, n. 5, p. 1, doi. 10.1038/s41389-021-00324-z
- By:
- Publication type:
- Article
CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers.
- Published in:
- Nature Communications, 2017, v. 8, n. 6, p. 15916, doi. 10.1038/ncomms15916
- By:
- Publication type:
- Article
PAF-Wnt signaling-induced cell plasticity is required for maintenance of breast cancer cell stemness.
- Published in:
- Nature Communications, 2016, v. 7, n. 2, p. 10633, doi. 10.1038/ncomms10633
- By:
- Publication type:
- Article
Cyclin E is a more powerful predictor of breast cancer outcome than proliferation.
- Published in:
- Nature Medicine, 2003, v. 9, n. 2, p. 152, doi. 10.1038/nm0203-152
- By:
- Publication type:
- Article
Histone modification profiling in breast cancer cell lines highlights commonalities and differences among subtypes.
- Published in:
- BMC Genomics, 2018, v. 19, p. 1, doi. 10.1186/s12864-018-4533-0
- By:
- Publication type:
- Article
LMW-E/CDK2 Deregulates Acinar Morphogenesis, Induces Tumorigenesis, and Associates with the Activated b-Raf-ERK1/2-mTOR Pathway in Breast Cancer Patients.
- Published in:
- PLoS Genetics, 2012, v. 8, n. 3, p. 1, doi. 10.1371/journal.pgen.1002538
- By:
- Publication type:
- Article
A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 4, p. 890, doi. 10.1007/s10637-015-0244-4
- By:
- Publication type:
- Article
DEAR1 Is a Dominant Regulator of Acinar Morphogenesis and an Independent Predictor of Local Recurrence-Free Survival in Early-Onset Breast Cancer.
- Published in:
- PLoS Medicine, 2009, v. 6, n. 5, p. 1, doi. 10.1371/journal.pmed.1000068
- By:
- Publication type:
- Article
Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53.
- Published in:
- Oncogene, 2001, v. 20, n. 2, p. 147, doi. 10.1038/sj.onc.1204062
- By:
- Publication type:
- Article
UCN-01-mediated G1 arrest in normal but not tumor breast cells is pRb-dependent and p53-independent.
- Published in:
- Oncogene, 1999, v. 18, n. 41, p. 5691, doi. 10.1038/sj.onc.1202948
- By:
- Publication type:
- Article
Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53.
- Published in:
- Oncogene, 1998, v. 17, n. 18, p. 2393, doi. 10.1038/sj.onc.1202322
- By:
- Publication type:
- Article
EVI1 splice variants modulate functional responses in ovarian cancer cells.
- Published in:
- Molecular Oncology, 2013, v. 7, n. 3, p. 647, doi. 10.1016/j.molonc.2013.02.008
- By:
- Publication type:
- Article
Semi-high throughput method of measuring proteasome inhibition in vitro and in cultured cells.
- Published in:
- Cell Biology & Toxicology, 2011, v. 27, n. 2, p. 123, doi. 10.1007/s10565-010-9175-1
- By:
- Publication type:
- Article
Deregulation of cyclin E meets dysfunction in p53: Closing the escape hatch on breast cancer.
- Published in:
- Journal of Cellular Physiology, 2006, v. 209, n. 3, p. 686, doi. 10.1002/jcp.20818
- By:
- Publication type:
- Article
Novel splice variants of cyclin E with altered substrate specificity.
- Published in:
- Nucleic Acids Research, 2000, v. 28, n. 23, p. e101, doi. 10.1093/nar/28.23.e101
- By:
- Publication type:
- Article
Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Staurosporine is chemoprotective by inducing G1 arrest in a Chk1- and pRb-dependent manner.
- Published in:
- Carcinogenesis, 2013, v. 34, n. 10, p. 2244, doi. 10.1093/carcin/bgt186
- By:
- Publication type:
- Article
Differential mRNA expression of the human DNA methyltransferases (DNMTs) 1, 3a and 3b during the G0/G1 to S phase transition in normal and tumor cells.
- Published in:
- Nucleic Acids Research, 2000, v. 28, n. 10, p. 2108, doi. 10.1093/nar/28.10.2108
- By:
- Publication type:
- Article
Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2− metastatic breast cancer patients compared to endocrine therapy alone in the second‐line setting: A large institutional study.
- Published in:
- International Journal of Cancer, 2022, v. 150, n. 12, p. 2025, doi. 10.1002/ijc.33959
- By:
- Publication type:
- Article